Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.52 |
| ▸ | PPARA | Q07869 | 15/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12130115 | 0.87 | PPARG (0.48) | PPARGPPARA | |
| SCHEMBL1343478 | 0.87 | PPARG (0.48) | PPARGPPARA | |
| SCHEMBL12130116 | 0.87 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL1342248 | 0.86 | PPARG (0.52) | PPARGPPARAPTPN1 | |
| SCHEMBL1340732 | 0.86 | PPARG (0.60) | PPARGPPARA | |
| SCHEMBL1343316 | 0.85 | AURKA (0.44) | PPARGPPARA | |
| SCHEMBL4941873 | 0.84 | MAPT (0.40) | PPARGPPARASLC6A9ALDH1A1CYP2D6 | |
| SCHEMBL1343050 | 0.81 | PPARG (0.59) | PPARGPPARAPTPN1SLC6A9 | |
| SCHEMBL1343918 | 0.80 | PPARA (0.60) | PPARGPPARA | |
| SCHEMBL13619017 | 0.78 | PPARG (0.47) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632846-B2 | the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) | 2009-12-15 | — | — | US | claimed |
| US-20080194564-A1 | Hexenoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Applications Thereof | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | claimed |
| JP-2007536290-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1742902-B1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| EP-1742902-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GmbH (DE) | 2007-01-17 | — | — | EP | claimed |
| WO-2005105724-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GMBH (DE) | 2005-11-10 | — | — | WO | claimed |
| US-8063067-B2 | Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof | MERCK PATENT GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063067-B2 | Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof | MERCK PATENT GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-7632846-B2 | the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) | 2009-12-15 | — | — | US | disclosed |
| US-7632846-B2 | the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) | 2009-12-15 | — | — | US | disclosed |
| US-7632846-B2 | the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20090286776-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | ZEILLER JEAN JACQUES | 2009-11-19 | — | — | US | disclosed |
| US-20090286776-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | ZEILLER JEAN JACQUES | 2009-11-19 | — | — | US | disclosed |
| US-20080194564-A1 | Hexenoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Applications Thereof | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194564-A1 | Hexenoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Applications Thereof | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194564-A1 | Hexenoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Applications Thereof | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1742902-B1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1742902-B1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1742902-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GmbH (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005105724-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | MERCK PATENT GMBH (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194564-A1 | Hexenoic Acid Derivatives, Processes for the Preparation Thereof, Pharmaceutical Compositions Comprising Them, and Therapeutic Applications Thereof | GPR119, LIPA, ALOX5 | PPARG 95/4885PPARA 81/4885PTPN1 3847/4885 |
| US-20090286776-A1 | HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF | GPR119, LIPA, ALOX5 | PPARG 95/4885PPARA 81/4885PTPN1 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.